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Abstract
Introduction This article aims to condense the lectures and
discussions from workshops on good reporting at IUGA
Como 2009 and ICS San Francisco 2009, providing
practical advice for the novice researcher summarising their
data for the first time.
Conclusions Drafting an abstract can be a time consuming
process. Formal guidance, such as CONSORT and
STROBE, exists for the kinds of information that should
be included regarding almost all designs of clinical trials.
Follow the abstract submission rules closely to avoid
outright rejection. Plan to highlight the novelty, scientific
merit and clinical impact of the work. Try not to overstate
the importance of the findings. Do not forget to publish the
work in a peer reviewed journal.
Keywords Abstractingandindexing.Clinicaltrials.
Congresses.Medicalsocieties.Peerreview
Introduction
Presentations at international scientific conferences such as
ICS and IUGA are the most important route for early
dissemination and discussion of research findings. Indeed
for many studies that never reach full text publication [1], and
in many regions where access to health care publications is
limited, the conference abstract may be the only easily
available record of the research. As if preparing a succinct
and accurate summary of one’s research is not challenging
enough, there is also a certain art to writing an abstract that
will appeal to conference scientific committees.
Over the last decade getting work accepted for oral
presentationateitherICSor IUGAbecame increasinglydifficult
(Fig. 1). In 2009 the ICS meeting in San Francisco received
1,003 abstract submissions and was able to accept only 284 for
oral presentation. The IUGA meeting was usually more
forgiving, with the 2009 Como meeting receiving 477
submissions and accepting 200 oral presentations.
Aims
In 2009 we held workshops at both meetings on good
reporting of research findings. Speakers included chairs and
members of ICS and IUGA scientific committees, specialty
journal editors and expert methodologists. With the April 1
deadline for submissions to the joint 2010 ICS/IUGA
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the lectures and discussions from those workshops into
practical advice for the novice researcher facing the
daunting task of summarising their data for the first time.
When to write an abstract
It is an important principle that abstracts presented at ICS or
IUGA should not have been previously presented interna-
tionally, nor should the abstracts have been indexed in a
published journal. Every year there is some overlap of
presentations between the two meetings, as well as with
other urological or gynaecological meetings, which wastes
the precious resource of podium time. It is a more strictly
enforced rule that studies that have been published in full,
even as an e-publication, should not be presented. Every
year some abstracts slip through, despite prior publication
[2, 3]. The reverse situation occurs when researchers
choose to submit an abstract before conducting any
analysis, or based on analysis of interim results. Each
abstract should contain original data, not merely a descrip-
tion of methodology. Reports of interim analyses may be
justified on safety grounds, but should ideally be led by an
independent data monitoring committee. Particularly for
randomised trials, conducting interim efficacy analyses
before completion of recruitment jeopardises the power
calculation of the study and compromises the equipoise of
the researchers [4]. Even for observational studies, waiting
for full recruitment and complete follow-up is usually
associated with a more powerful message.
Every year, very large numbers of abstracts are submit-
ted in the final hours before abstract submission closes. The
writing of a conference abstract is usually the first chance
for multiple authors to synthesise and reflect on complex
findings. Sufficient time should therefore be allotted for
multiple revisions, with a chance for all listed authors to
approve the final draft. Working right up to the deadline
may lead to gaps in the analysis and unnecessary
approximations. Although we have ourselves each been
guilty of last minute submissions, we would recommend
leaving as much time as possible for abstract preparation.
Find appropriate reporting guidance
The classic scientific format of Introduction, Methods,
Results, and Discussion (IMRaD) is adapted for abstracts at
both meetings, with extra stress placed on stating a clear
objective or hypothesis for the study. Within the IMRaD
structure more detailed guidance is available for the items
that ought to be included in the full report of a trial. The
EQUATOR Network collects and promotes such evidence-
based guidance for research reporting. The best known of
these recommendations is the CONSORT guideline [5].
Implementation of CONSORT has been shown to effec-
tively improve reporting of randomised controlled trials [6],
and it has been formally adopted for reporting of
randomised trials at the ICS/IUGA meeting [7]. A core set
of items suitable for inclusion in brief abstracts is also
available [8] and should be considered as a minimum
requirement. Most abstracts submitted to ICS and IUGA are
observational cohort, case control or cross-sectional studies.
The STROBE statement gives specific guidance for report-
ing research from each of these designs [9]. Other guidance
relevant to the continence field includes PRISMA for
systematic reviews and meta-analyses [10] and STARD
for diagnostic accuracy studies [11]. The EQUATOR
Network has collected many other useful examples [12].
Together these guidelines provide a framework for report-
ing of clinical research of most designs. Although, with the
exception of the CONSORT for abstracts, these guidelines
are intended for whole manuscripts, ICS and IUGA
abstracts are relatively long. This should allow authors to
fulfil most requirements. Failing to report these key items
prevents full evaluation of the work, and therefore limits the
impact of the study.
Avoid basic errors
Both societies provide detailed abstract submission rules
[7]. It is strongly advised to read these in detail before
starting the process of writing. Very few abstracts are
rejected outright, unless the authors failed to follow the
abstract submission rules. Abstracts must be in the correct
font, at the correct size, must not be too short or too long
and must follow the recommended structure. Importantly,
and seemingly obviously, abstracts for the ICS/IUGA
meeting should be related to either continence or
urogynaecology.
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Fig. 1 Total abstract submissions to the ICS meeting 2000–2009
(Data courtesy of Dan Snowdon)
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anonymous, which enhances the perception of fairness,
although it has an uncertain effect on the reliability of the
scoring system [13]. Every year abstracts are rejected
because authors disclose their names or their institution
within the text of the abstract. Describing the country or
region and the type of healthcare organisation should
provide sufficient information about the setting. Although
it is acceptable for abstracts to include self-citations, the
cited paper should not be referred to in the first person
possessive (e.g., ‘our previous work showed…’) in order to
maintain anonymity.
Drafting a clearly worded, readable abstract is difficult
even for native English speakers. While spelling errors and
solecisms will not rule out acceptance of high quality
science, there is evidence that reviewers are biased in
favour of well-written abstracts. Non-native English
speakers should therefore enlist native English speakers
or better still, professional medical writers to review their
drafts.
Appeal to the scientific committee
Abstracts are judged on three criteria: novelty, scientific
merit and clinical impact, which are allotted equal impor-
tance. Authors should bear these categories in mind when
drafting each section of the abstract. The process of scoring
abstracts is very intense for members of the scientific
committee. Each referee will be allocated approximately
300 abstracts to evaluate, with each abstract scored by
multiple referees to increase reliability. This amounts to
hundreds of thousands of words to be read over a 2-week
period. Since most committee members also have full-time
Table 1 Summary of suggestions for ICS/IUGA abstracts of clinical trials
Abstract Section Items to include
Title Identify the study design (e.g., randomised trial, prospective/
retrospective cohort, case control, cross-sectional study)
Hypothesis / aims of study Explain the clinical or scientific uncertainties addressed
Give the rationale for the design
Give a clear statement of the main objective
Study design, materials and methods Detail major eligibility criteria for participants
a
Indicate the setting for the study (without breaching anonymity)
Give the periods of recruitment and follow-up
Briefly explain the intervention or exposure
a
Briefly explain how and when outcomes were assessed
Give details of efforts to address potential sources of bias
(might include details of randomisation, blinding, validation of
questionnaires or data sources, training of assessors, follow-up
of non-responders, adjustment for confounding)
Explain the statistical analyses used, and how the sample
size was determined
Results Give the numbers of participants approached, the number recruited,
and the number followed up at each timepoint
a
Specify if recruitment is ongoing
Briefly give the major demographic characteristics of participants
a
Give a result for each outcome, with a measure of precision
(standard deviation, 95% confidence intervals), and indicate
the number of participants with missing data
a
Report any harms or adverse events
a
Interpretation of results Summarise the main findings
Realistically assess the importance of the findings, taking into
account the limitations of the study, including sources of
potential bias or imprecision
Give explicit examples of the clinical or translational relevance
Concluding message Explain how the study addressed the aim
aFor each group, where groups are compared
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each abstract is extremely limited.
The title is the first, and perhaps main chance to grab
the attention of the tired overworked referees. Formal
guidance, such as STROBE, recommends that titles
should indicate the study design (e.g., ‘Ap r o s p e c t i v e
cohort study of snake oil for stress incontinence’). Popular
alternatives include phrasing the title as a question in
order to highlight the novelty and aims (e.g., ‘Does snake
oil cure stress incontinence?’); giving a conclusive
statement summarising the main finding (e.g., ‘Snake oil
is ineffective for stress incontinence’); or some combina-
tion of these approaches.
After the title, readers and reviewers tend to focus next
on the aims and conclusions. It is important that the title fits
with the aim and that the conclusion directly addresses the
aim. The reviewers are unlikely to be familiar with the
entire world literature on your topic, so the background is a
chance to briefly explain the clinical or scientific uncer-
tainties addressed and the rationale for the design. It is
helpful to be specific about the main hypothesis.
When there are multiple hypotheses and multiple out-
come measures it may be tempting to break the study into
two or more abstracts, so called salami slicing [14]. This is
explicitly forbidden in the abstract rules. The objective
should be to present the single strongest abstract, with the
best chance of being rewarded with a podium presentation
or discussed poster. If one study was conducted, with one
sample, then there should be just one abstract reported.
The scientific merit of an abstract is in part
determined by the study design and in part by the
clarity of the results and methods sections. The worst
reported randomised trial will still score higher than the
best case report. The formal reporting guidance (CON-
SORT, STROBE, STARD) appropriate to each study
design will help decide what information is necessary in
the limited space available. A well-designed table or
figure will often be the clearest way to present the
actual data. It is important that a table should neither
contain too many data, making it unreadable, nor should
it repeat the text.
The conclusion is the final chance to demonstrate the
clinical impact of the work. Authors should therefore give
explicit examples of the clinical or translational relevance.
Many abstracts overstate the importance of their findings,
making claims that would not withstand full peer review
[2]. It is an egregious error to claim that an intervention
tested is ‘safe and effective’ if it is based on one centre, one
surgeon or only a small case series.
Table 1 summarises the types of information that might
be included in each section of an ICS/IUGA abstract for a
clinical trial, adapted from the CONSORT, and STROBE
statements.
Conclusions
Providing abstracts follow the submission rules, they are
unlikely to be rejected outright. Formal guidance exists for
almost all study designs and should help identify the kinds
of information that need to be included in each section of
the abstract. Despite the tips and suggestions made here,
podium time is at a premium, and there are no guarantees of
acceptance for oral presentation.
Getting an abstract accepted is only the first step in
disseminating research findings. It is even more important
to submit for publication. Getting the paper ready for
publication can be good preparation for fielding questions
from the conference floor. Conversely questions from the
floor may be a good indicator of the kinds of queries that
will be raised in the peer review process. Great abstracts
can still make poor presentations, and there is a plethora of
good advice for preparing slides [15–17].
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